Results 121 to 130 of about 261,496 (309)

Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry

open access: yesChemMedChem, EarlyView.
This review highlights the rationale behind multitarget drug design as a promising approach to address diseases with complex etiologies. By combining pharmacophore features from different single‐target drugs, multitarget compounds can interact with multiple biological targets simultaneously.
Sadık Hüseyin Cemali   +7 more
wiley   +1 more source

Recent advances in immunoassay technologies for the detection of human coronavirus infections. [PDF]

open access: yesFront Cell Infect Microbiol, 2022
Wang D   +10 more
europepmc   +1 more source

An Experimental Model for Dilated Cardiomyopathy after Rabbit Coronavirus Infection [PDF]

open access: bronze, 1992
Lorraine K. Alexander   +3 more
openalex   +1 more source

Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early ...
Antoni Bayes‐Genis   +13 more
wiley   +1 more source

Mathematical modeling of the spread of the coronavirus under strict social restrictions

open access: yesMathematical Methods in the Applied Sciences, EarlyView., 2021
We formulate a simple susceptible‐infectious‐recovery (SIR) model to describe the spread of the coronavirus under strict social restrictions. The transmission rate in this model is exponentially decreasing with time. We find a formula for basic reproduction function and estimate the maximum number of daily infected individuals.
Mo'tassem Al‐arydah   +3 more
wiley   +1 more source

Approbation of the Technology for Constructing Means of Express Indication of New Especially Dangerous

open access: yesВестник войск РХБ защиты
Catastrophic pandemic of the particularly dangerous coronavirus SARS-CoV-2 in 2020–2022 and the unexpected  spread of the monkeypox pathogen from Africa in 2022, demonstrate the need for an adequate response to biological  threats that have exotic ...
A. A. Petrov   +6 more
doaj   +1 more source

Exploring the Potential Medicinal Benefits of Ganoderma lucidum: From Metabolic Disorders to Coronavirus Infections. [PDF]

open access: yesFoods, 2023
Ekiz E   +10 more
europepmc   +1 more source

Exploring the long‐term effects of COVID‐19 in patients with epilepsy: A multicenter Italian observational study

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Coronavirus disease‐19 (COVID‐19), caused by SARS‐CoV‐2, has led to a global pandemic since December 2019. People with epilepsy (PwE) face higher risks of severe COVID‐19 outcomes and may be more vulnerable to long‐term neurological and psychiatric effects. Methods This multicenter, retrospective cohort study reviewed medical records
Fedele Dono   +8 more
wiley   +1 more source

Serological Survey of Retrovirus and Coronavirus Infections, including SARS-CoV-2, in Rural Stray Cats in The Netherlands, 2020-2022. [PDF]

open access: yesViruses, 2023
Duijvestijn MBHM   +9 more
europepmc   +1 more source

Effectiveness of perampanel as the only adjunctive anti‐seizure medication in adults: Final results from the observational PERPRISE study in Germany

open access: yesEpilepsia Open, EarlyView.
Abstract Objective The PERPRISE study (Study 509; NCT04202159) was a prospective, observational, non‐interventional study in a real‐world setting in Germany. This study was conducted to evaluate the effectiveness of perampanel as the only adjunctive treatment for 12 months in patients aged ≥18 years with focal to bilateral tonic–clonic seizures (FBTCS)
Bernhard J. Steinhoff   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy